Abstract:IMPORTANCE Recent advances in newborn screening (NBS) have improved the diagnosis of inborn errors of metabolism (IEMs); however, many potentially treatable IEMs are not included on NBS panels, nor are they covered in standard, first-line biochemical testing. OBJECTIVE To examine the utility of untargeted metabolomics as a primary screening tool for IEMs by comparing the diagnostic rate of clinical metabolomics with the recommended traditional metabolic screening approach. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study compares data from 4464 clinical samples received from 1483 unrelated families referred for trio testing of plasma amino acids, plasma acylcarnitine profiling, and urine organic acids (June 2014 to October 2018) and 2000 consecutive plasma samples from 1807 unrelated families (July 2014 to February 2019) received for clinical metabolomic screening at a College of American Pathologists and Clinical Laboratory Improvement Amendments-certified biochemical genetics laboratory. Data analysis was performed from September 2019 to August 2020. EXPOSURES Metabolic and molecular tests performed at a genetic testing reference laboratory in the US and available clinical information for each patient were assessed to determine diagnostic rate. MAIN OUTCOMES AND MEASURES The diagnostic rate of traditional metabolic screening compared with clinical metabolomic profiling was assessed in the context of expanded NBS. RESULTS Of 1483 cases screened by the traditional approach, 912 patients (61.5%) were male and 1465 (98.8%) were pediatric (mean [SD] age, 4.1 [6.0] years; range, 0-65 years). A total of 19 families were identified with IEMs, resulting in a 1.3% diagnostic rate. A total of 14 IEMs were detected, including 3 conditions not included in the Recommended Uniform Screening Panel for NBS. Of the 1807 unrelated families undergoing plasma metabolomic profiling, 1059 patients (58.6%) were male, and 1665 (92.1%) were pediatric (mean [SD] age, 8.1 [10.4] years; range, 0-80 years). Screening identified 128 unique cases with IEMs, giving an overall diagnostic rate of 7.1%. In total, 70 different metabolic conditions were identified, including 49 conditions not presently included on the Recommended Uniform Screening Panel for NBS. CONCLUSIONS AND RELEVANCE These findings suggest that untargeted metabolomics provided a 6-fold higher diagnostic yield compared with the conventional screening approach and identified a broader spectrum of IEMs. Notably, with the expansion of NBS programs, traditional metabolic testing approaches identify few disorders beyond those covered on the NBS. These data support the capability of clinical untargeted metabolomics in screening for IEMs and suggest that broader screening approaches should be considered in the initial evaluation formetabolic disorders.

2-Pyrrolidinone and Succinimide As Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis.

Clinical Metabolomics to Segregate Aromatic Amino Acid Decarboxylase Deficiency from Drug-Induced Metabolite Elevations

Clinical Metabolomic Profiling For The Diagnosis Of Neurometabolic Disorders For Global Development Delay, Seizures

Diagnosis of adenylosuccinate lyase deficiency by metabolomic profiling in plasma reveals a phenotypic spectrum.

Succinic semialdehyde dehydrogenase deficiency: review of the clinical phenotype and metabolic/genomic approach to diagnosis

Comprehensive metabolomics analysis reveals novel biomarkers and pathways in falsely suspected glutaric aciduria Type-1 newborns

Two inborn errors of metabolism in a newborn: glutaric aciduria type I combined with isobutyrylglycinuria

A pilot study to estimate incidence of guanidinoacetate methyltransferase deficiency in newborns by direct sequencing of the GAMT gene

Exploration of urine metabolic biomarkers for new-onset, untreated pediatric epilepsy: A gas and liquid chromatography mass spectrometry-based metabolomics study

Untargeted Metabolomic Profiling Reveals Multiple Pathway Perturbations and New Clinical Biomarkers in Urea Cycle Disorders

Untargeted Metabolomics As an Unbiased Approach to the Diagnosis of Inborn Errors of Metabolism of the Non-Oxidative Branch of the Pentose Phosphate Pathway.

Aromatic L-Amino Acid Decarboxylase Deficiency Diagnosed by Clinical Metabolomic Profiling of Plasma

Elucidation of the complex metabolic profile of cerebrospinal fluid using an untargeted biochemical profiling assay.

Untargeted Metabolomic Analysis for the Clinical Screening of Inborn Errors of Metabolism

Comparison of Untargeted Metabolomic Profiling vs Traditional Metabolic Screening to Identify Inborn Errors of Metabolism

Monitoring the Treatment of Urea Cycle Disorders Using Phenylbutyrate Metabolite Analyses: Still Many Lessons to Learn.

Targeting the Metabolic Profile of Amino Acids to Identify the Key Metabolic Characteristics in Cerebral Palsy.

[Retrospective Analysis on Clinical Data and Genetic Variations of Patients with Beta-Ketothiolase Deficiency].

Astrocytic GABA Transporter 1 Deficit in Novel SLC6A1 Variants Mediated Epilepsy: Connected from Protein Destabilization to Seizures in Mice and Humans.

[A Pilot Study of Selective Screening for High Risk Children with Inborn Error of Metabolism Using Tandem Mass Spectrometry in China].

Metabolomic Profiling of Human Urine as a Screen for Multiple Inborn Errors of Metabolism.